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Abstract. 
 
Oxadiazole replacement of an amide linkage in an RARα agonist template 1, followed by 
lead optimisation, has produced a highly potent and selective RARβ agonist 4-(5-(4,7-
dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (10) with good oral 
bioavailability in the rat and dog. This molecule increases neurite outgrowth in vitro and 
induces sensory axon regrowth in vivo in a rodent model of avulsion and crush injury, 
and thus has the potential for the treatment of nerve injury. 
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There are no effective treatments for nerve injuries including spinal cord injuries 
(SCI), stroke, and peripheral nerve injuries.  However it has been shown
1
 that stimulating 
the retinoid signalling pathway in animal models of nerve injury leads to axonal 
outgrowth and functional recovery.  This pathway is activated by retinoic acid (RA) 
binding to retinoic acid receptors (RAR) that acts in the nucleus to drive the synthesis of 
RNA and hence produce proteins for axonal outgrowth.  Corcoran et al.,
2
 have shown 
that RARβ signalling is required for retinoid mediated neurite outgrowth of neurons. In 
contrast, signalling by RARα, RARγ or the RXRs has no effect on this action. It has been 
shown 
3
 that the RARβ agonist, CD2019, can activate the RARβ receptor in a dose 
dependent manner. This initiates axonal outgrowth in models of nerve injury and leads to 
functional recovery. However CD 2019 is a highly lipophilic compound that is not 
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significantly orally bioavailable and shows only weak to moderate selectivity over RARα 
and RARγ receptors.  AG 261066, more recently described as a selective RARβ agonist 
is less potent than CD 2019 and less selective than the latter over RARα (Table 4).  Our 
aim was to identify a more drug-like, highly potent and selective RARβ agonist that was 
orally bioavailable and which had the potential to be useful in the treatment of nerve 
injury. 
Recently, we discovered a novel and selective RARα agonist 4-[(3,5-dichloro-4-
ethoxybenzoyl)amino]benzoic acid 1.  This template was the basis of a lead optimisation 
exercise which led to an orally bioavailable and highly potent RARα agonist with high 
selectivity against RARβ and RARγ.4 As part of this exercise, it was decided to modify 
the amide linkage between the two rings by replacing it with a variety of 5-membered 
heterocycles (Table 1).  Changing the amide linkage in 1 to thiazole and imidazole gave 
derivatives 2  and 3 that were weakly active as RARα agonists, but were more potent than 
amide 1 as RARβ agonists, although only weakly selective for RARβ vs RARα.  The 
oxazole 4 was >40-fold more potent than 1 as an RARβ agonist and had similar agonist 
potency for all three subtypes. 
    
Table 1. Heterocyclic derivatives in RAR ,  and  transactivation assays. a 
                   
Het
1  
a
 Transactivation assays for the RAR alpha, beta and gamma receptors were performed using each of the 
mouse RAR ligand binding domains. Values usually obtained from three separate experiments.  Errors in these 
assays are approximately 20% of the mean values. Transactivation Assays details see Supplementary data and 
reference 4. ATRA is all trans retinoic acid.  
b 
The EC50 ratios of to  and to 
compd Het  EC50 
  
nM
 a
 
 
EC50 
 nM 
a   

Fold 
Selectivity for 
 over  b 
 EC50  
nM 
a 

Fold 
Selectivity for 
 over  b 
cLogP
 d
 
   ATRA              - 1.9  1.2  1.56 0.9  0.75  
1 - 46  1227  0.037 30000  24 4.4 
2 
 
240 
c 
 120  2 160  1.3 6.1 
3 
 
594 
c
 
 
 423  1.4 ND - 5.6 
4 
 
60  28  2.1 45  1.6 5.5 
5 
 
  18 
c
 1.5 12 28 19 5.1 
6 
 
31 110 0.28 5.4 0.05 5.1 
7 
 
58 63 0.92 150 2.4 4.3 
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c 
Compound behaves as a partial agonist relative to the amplitude of the normalising ATRA output. All other 
compounds were determined to be full agonists with their maximum upper asymptote within 20% of that found 
for ATRA.
 
d 
reference 9. 
Surprisingly however, increasing the number of heteroatoms in the heterocyclic 
ring to give the oxadiazole 5 resulted in a highly potent RARβ agonist and that had 12- 
and 19-fold selectivity as an agonist over RARα and RAR respectively.  This RARβ 
agonist selectivity and potency was lost when the isomeric 1,2,4-oxadiazol-5-yl benzoic 
acid derivative 6 and the 1,3,4-oxadiazol-2-yl benzoic acid compound 7 were examined. 
 
Table 2 1,2,4-oxadiazol-3-yl benzoic acid derivatives in RAR ,  and  transactivation 
assays
a
 
N
N
O
CO
2
H
X
  
 a, b, c, d
 See Table 1  
compd X  EC50 
  
nM
 a
 
 
EC50 
 nM 
a   

Fold 
Selectivity for 
 over  b 
 EC50  
nM 
a 

Fold 
Selectivity for 
 over  b 
cLogP
 d
 
   ATRA              - 1.9  1.2  0.9  0.6 0.5  
5  
 
1.5    18 
c
 28 12 19 5.1 
8  
 
4200 18 17 0.0043 0.0041 7.2 
9  
 
1.4   4  3 2.8 2.1 7.2 
10  
 
1.9  26  11 13 5.6 5.3 
11  
 
2.5  19  5.3  7.6 2 5.3 
12  
 
3.4  30 6.3 9 2 5.8 
13  
 
11 114 83 10 7.5 4.1 
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To try and exploit the selective and potent RARβ agonist activity of the 1,2,4-
oxadiazol-3-yl benzoic acid derivative 5, a series of replacements for the 3,5-dichloro-4-
ethoxyphenyl ring with other heterocyclic and aryl rings found in known RAR agonists 
were investigated (Table 2). The 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene ring 
used in AM580,
5 
the 3,5 di-
t
butylphenyl ring in Am555,
5 
the 4,7-dimethylbenzofuran ring 
in ER38925
6
 and the 4-trifluoromethyl-7-fluorobenzofuran ring found in E6060,
7
 were 
investigated. 
 
Relative to 5, derivative 8 lost >2700-fold in potency as a RARβ agonist whilst 
retaining most of its potency at RAR. Compound 9 which retained good RARβ agonist 
potency, lost all RARβ selectivity and was essentially a potent pan-RAR agonist having a 
similar potency at all three subtypes.  In contrast, the 4,7-dimethylbenzofuran derivative 
10 maintained a similar potency and selectivity profile to 5 and as we were keen to move 
away from the dichlorophenyl motif found in a number of herbicides, this now became 
our lead compound.   
  
Compared to our lead 10, the 4-trifluoromethyl-7-fluorobenzofuran 11 and the 
benzothiophene 12 analogues, are less RARβ / RARα selective while the benzoxazole  
derivative 13 is less potent as a RARβ agonist (Table 2). 
 
In an attempt to increase further the selectivity and agonist potency of compound 
10, a series of substitutions in the benzoic acid portion of the template were investigated 
(Table 3).  The 2-fluoro compound 14 had a similar level of potency to 10 but lost some 
RARβ selectivity (Table 3) when compared to 10.  The 2-methyl 15, 3-fluoro 16 and 3-
methyl 17 derivatives all lost considerable potency as RARβ agonists when compared to 
10.     
 
Table 3 Derivatives of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic 
acid in the RAR ,  and  transactivation assays a 
 
    a, b, d
 See Table 1 
 
compd R EC50 
  
nM
 a
 
 EC50 
 nM 
a   
Fold Selectivity 
for  over  b 
 EC50  
nM 
a 
Fold Selectivity 
for  over  b 
cLogP
 d
 
10  H 1.9  26  11 13 5.6 5.3 
14  2-F 2.2  16  8.4  7.3 3.8 5.1 
15  2-Me 14  89  25 6.4 1.8 5.5 
16  3-F 11  61 3.7 5.5 0.33 5.5 
17  3-Me 47  600  14  13 0.3 5.5 
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With this information and other data not shown, it became apparent that substitution in 
the benzoic acid ring in this series did not increase potency at RAR, which is in contrast 
to observations made in the analogous RARα agonist series.4  
 
The lead RARagonist 10 has a high potency at RAR (similar potency to 
ATRA) and behaves as a full agonist.  It has a selectivity for RAR over RAR of 13-
fold, while selectivity for RAR over RAR is 5.6-fold.  
  
Table 4 Selective RARβ agonists 
AC 261066 CD 201910  
 
 
 
 
 
 
 
 
  
a, b, d
 See Table 1. 
Comparison of 10 with the selective RARβ agonist AC-2610668 showed that in 
our hands, 10 is a more potent and selective RARβ agonist (Table 4).  Whilst compound 
10 is marginally less potent than CD 2019, it has a better selectivity for RARβ over 
RARα and RARγ and is over two orders of magnitude less lipophilic.  The more drug-
like template present in 10 translates into a good in vitro and in vivo profile for this 
RARβ agonist (Table 5).  In comparison to the mouse transactivation data shown in Table 
4, we also confirmed that 10 had a similar RARβ potency (EC50 = 2.05 nM), similar fold 
selectivity for RARβ over RARα (23 fold) and for RARβ over RARγ (5 fold) against the 
human RAR ligand-binding domains,
4 
before further predevelopment studies were 
investigated. 
 
Table 5 Physico-chemical and in vitro properties of RARβ agonist 10 
 
 
 
 
 
a
 Measured by shake flask method. 
b 
as the amorphous sodium salt.  
c
 MDR1-MDCK cell line. 
d 
Cyp450 inhibition profile for isoforms 1A2, 2C9, 2C19, 2D6, 3A4. 
e 
Human microsomes incubated with the test compound at 37°C in the presence of the co-factor, NADPH. 
The data is the mean on 5 separate experiments. Compound disappearance monitored over 45 min period.  
SEM is less than 10% of the mean values. 
For 
a, b, c, d, e
 see reference 9 
compd EC50 
  
nM
 a
 
 EC50 
 nM 
a   
 EC50  
nM 
a 
Fold 
Selectivity for 
 over  b 
Fold 
Selectivity for 
 over  b 
cLogP
 d
 
10 1.9 26 11 13 5.6 5.3 
AC 261066 12 70 33 5.8 2.8 4.9 
CD 2019 0.83 9.2 1.6 11 1.9 8.0 
LogD
 a
 
7.4 
Solubility
b
 
µM 
pH 7.4
 
MDCK
c
 
Papp 
x 10
-6
 cm/s
 
MDCK
c
 
asymmetry 
ratio
 
Cyp450
d
 
IC50  
M 
Human Clint
 e
  
µL/min/mg 
protein 
2.8 >100 28 0.8 >25 <1 
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The potential drug candidate 10 has excellent physico-chemical properties.  It is 
sufficiently water soluble (>100 µM as the sodium salt) and showed good permeability. 
The efflux ratios obtained from bi-directional permeability tests was close to unity 
indicating that 10 is likely not a PGP substrate. With no significant inhibition IC50 > 
25M against five Cyp450 isozymes (1A2, 2C9, 2C19, 2D6, 3A4), a human and mouse 
plasma protein binding of 98% and 95% respectively and showing very high stability in 
human microsomes, this compound was progressed to pharmacokinetic studies.  
 
Table 6. Pharmacokinetic data for Compound 10 in Rat and Dog.
12
 
 
 
 
 
 
 
 
a
 iv dose 0.5 mg/kg administered in 4% DMSO, 38% PEG-400, 58% (0.9%) NaCl.  Oral doses of 1, 3 and 
10 mg/kg prepared in 8% ethanol and 92% PEG-400. 
b
 Based on mean of data obtained at 1, 3 and 10 mg/kg oral dose levels in comparison to iv dose of 0.5 
mg/kg. 
c
 iv dose 0.5 mg/kg administered in 2% DMSO, 98% aqueous hydroxypropyl--cyclodextrin (22.5% w/v).  
Oral dose 3 mg/kg administered in 3% DMSO, 97% aqueous hydroxypropyl--cyclodextrin (22.5% w/v).  
For assay description 
a, c, 
see reference 4. 
 
As shown in Table 6 compound 10 was found to possess a promising 
pharmacokinetic profile in both rat and dog.  It demonstrated a low rate of blood 
clearance, a moderate half-life and good oral bioavailability.  It was also found to 
penetrate the CNS, with nearly equivalent amounts detected in brain tissue when 
compared to plasma, 8h after dosing orally to rats.  
 
In the HEPG2 cell toxicity assay 10 was found to be completely devoid of alerts 
at the highest concentration tested (50M).  Furthermore, in a binding assay for HERG 
channels, the compound, demonstrated no inhibition at 10M.  Genetic toxicity testing of 
the material showed that it was inactive in bacterial cytotoxicity tests up to 100M and in 
an Ames test in three bacterial strains.  Similar, negative results were obtained in an in 
vitro micronucleus test in CHO-K1 cells, in both the presence and absence of S9.   
 
Synthesis and characterisation of compounds in Table 1-3 have been described
10
 
and involve standard preparation of the 5-membered heterocyclic rings.  This is 
illustrated by the preparation of our lead oxadiazole 10 outlined in Scheme 1. 
 
 
 
 
 
 
 
 
 
Species Clearance   
mL/h/kg 
Volume 
Distribution ss   
mL/kg 
t1/2   
h 
Tmax   
h 
Fraction 
absorbed 
% 
rat
 a
 3.7 0.41 1.4 1.7 80
 b
 
dog
 c
 1.1 0.23 2.5 1.0 45 
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Scheme 1 Synthesis of oxadiazole 10.  
10
a
b
65%
99%
 
 
Reagents and conditions: (a) T3P, EtOAc, DMF, Et3N, 0 
o
C, then warmed to 90°C and stirred for 18 h; (b) 
LiOH (2 M, aq.,), THF, 40°C for 20 h. then at RT HCl (1 M) added (see Supplementary data for full 
experimental and spectroscopic details). 
 
Compound 10 was evaluated for neurite outgrowth/branching in cerebellar 
cultures.  Cerebellar cultures grown on a monolayer of CHO-MAG were treated with 
RAR agonists and neurite outgrowth was assessed by immunostaining and neurite 
length quantification.
10
 The compound increased neurite length in a dose dependant 
manner (Figure 1) and thus has the potential to be useful in the treatment of nerve injury. 
 
Figure 1 Effects of RARβ agonists 10 on neurite outgrowtha       {image single,column} 
     
a 
Cerebellar neurons grown on a monolayer of CHO-MAG cells were treated for 24hr with either vehicle 
(V) or increasing doses of RARβ agonists (1 x 10 -8-1 x10-6M). Both RARβ agonists increase neurite 
outgrowth in a dose dependant manner. Results are means from 3 independent experiments. Statistical 
analysis was done using Student’s t-test between vehicle and each drug’s highest dose. Error bars are SEM 
and **p≤0.001, * p≤0.01. 
 
The novel RAR agonist 10 has also been demonstrated to be capable of inducing 
sensory axon regrowth in vivo in a rodent model of avulsion as shown in Figure 2, where 
avulsion is defined as the traumatic tear of nerve roots from the spinal cord causing injury.  
Rats were trained for two weeks prior to surgery in behavioural tasks and scores were 
recorded the day before surgery, the day after surgery and then weekly, for four weeks.  
Surgery was performed as previously described.
11,12
  In a sticky tape task, the time taken 
to sense and remove the tape from the paw of the lesioned forelimbs was measured. From 
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week three of treatment, significantly lower latencies were observed with the injured 
forelimbs of compound 10 treated rats (3mg/kg, po) compared to vehicle treated ones. In 
locomotor tasks, the number of foot slips in a horizontal ladder made by the injured 
forelimb of the compound 10 treated rats was also measured.  This parameter was found 
to be markedly lower than that of vehicle treated rats from week two.  Further details and 
data on an in vivo model of crush injury will be presented in due course. 
 
Figure 2 Effects of oral administration of compound 10 in sensory and locomotor 
functions in avulsed rats
a
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 Dose 3mg/kg, po, three times a week, every other day. Data represent mean ±SEM of n=8, **p ≤0.005, 
***p ≤0.001. Two-way repeated-measures ANOVA, Tukey’s post-hoc test.  
 
In summary, replacing the amide linkage between the two aromatic rings in our 
selective RARα agonist template with 5-memebered heterocycles, gave compounds 
which were selective as RARβ agonists. SAR exploration of the oxadiazole based series 
led to potent and selective RARβ agonists.  In particular compound 10, which will 
henceforth be referred to as C286, possesses favourable physicochemical properties with 
an oral bioavailability of >40% in both rats and dogs, a good overall PK profile and drug-
10 (3mg/kg) 
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like properties. Furthermore, it has been shown to be inactive in cytotoxicity and 
genotoxicity screens. It has also been demonstrated here to increase neurite outgrowth in 
vitro and induce sensory axon regrowth in vivo in a rodent model of avulsion and crush 
injury and thus warrants further consideration as a potential therapeutic agent for the 
treatment of nerve injury.  
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